A5088717584- Nanoplatforms for cancer theranostics
- Nanoparticle-Based Drug Delivery
- Immunotherapy and Immune Responses
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- Photodynamic Therapy Research Studies
- Protein Degradation and Inhibitors
- Dendrimers and Hyperbranched Polymers
- Multiple Myeloma Research and Treatments
- Advanced biosensing and bioanalysis techniques
- Extracellular vesicles in disease
- RNA Interference and Gene Delivery
- Molecular Communication and Nanonetworks
- Advanced Proteomics Techniques and Applications
- Protease and Inhibitor Mechanisms
- Photoacoustic and Ultrasonic Imaging
- 3D IC and TSV technologies
- Electronic Packaging and Soldering Technologies
- Photoreceptor and optogenetics research
- Ovarian cancer diagnosis and treatment
- Testicular diseases and treatments
- Intraperitoneal and Appendiceal Malignancies
- Ubiquitin and proteasome pathways
Ewha Womans University
2024-2025
Korea University
2020-2024
Korea Institute of Science and Technology
2002-2024
Immune checkpoint blockade is a promising approach for cancer immunotherapy, but many patients do not respond due to the immunosuppressive tumor microenvironment (ITM). Herein, we propose visible-light-triggered prodrug nanoparticles (LT-NPs) reversing ITM into high immunogenic tumors potentiate immunotherapy. The photosensitizer (verteporfin; VPF), cathepin B-specific cleavable peptide (FRRG), and doxorubicin (DOX) conjugates are self-assembled LT-NPs without any additional carrier...
Rationale: Cancer immunotherapy combining immune checkpoint blockade (ICB) with chemotherapeutic drugs has provided significant clinical advances. However, such combination therapeutic regimen suffered from severe toxicity of both and low response rate patients. In this study, we propose anti-PD-L1 peptide-conjugated prodrug nanoparticles (PD-NPs) to overcome these obstacles current cancer immunotherapy. Methods: The functional peptide, consisted peptide cathepsin B-specific cleavable is...
Exosomes are cellular components with promising uses in cancer diagnostics and therapeutics, their imaging tracking essential to study biological properties. Herein, we report on an situ one-step fluorescence labeling strategy for exosomes via bioorthogonal click chemistry. First, exosome donor cells were treated tetraacetylated N-azidoacetyl-d-mannosamine (Ac4ManNAz) generate unnatural azide groups (−N3) surface metabolic glycoengineering. Then, the labeled near-infrared fluorescent...
Synergistic immunotherapy of immune checkpoint blockade (ICB) and immunogenic cell death (ICD) has shown remarkable therapeutic efficacy in various cancers. However, patients show low response rates undesirable outcomes to these combination therapies owing the recycling mechanism programmed death-ligand 1 (PD-L1) systemic toxicity ICD-inducing chemotherapeutic drugs. Herein, we propose all-in-one glycol chitosan nanoparticles (CNPs) that can deliver anti-PD-L1 peptide (PP) doxorubicin (DOX)...
Immunogenic cell death (ICD) is a crucial approach to turn immunosuppressive tumor microenvironment (ITM) into immune-responsive milieu and improve the response rate of immune checkpoint blockade (ICB) therapy. However, cancer cells show resistance ICD-inducing chemotherapeutic drugs, non-specific toxicity those drugs against reduce immunotherapy efficiency.
Direct local delivery of immunogenic cell death (ICD) inducers to a tumor site is an attractive approach for leading ICD effectively, due enabling the concentrated site. Herein, we prepared doxorubicin (DOX)-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) using different molecular weight PLGA (7000 g/mol and 12,000 g/mol), showing drug release kinetics. The kinetics DOX might differently stimulate cell-specific immune response by releasing damage-associated patterns (DAMPs),...
Abstract Photodynamic therapy shows promise for glioma treatment with powerful efficacy and low resistance, however, its effectiveness is significantly lowered by inadequate light delivery through the skull. Herein, a needle‐type implantable microLED device cathepsin B‐responsive prodrug nanoparticles (PNPs) are newly exploited glioma's chemo‐photodynamic combination therapy. The containing four small LEDs on tip of guide needle can be implanted into center tissues without large area opening...
Immunogenic cell death (ICD) is a powerful trigger eliciting strong immune responses against tumors. However, traditional chemoimmunotherapy (CIT) does not last long enough to induce sufficient ICD, and also guarantee the safety of chemotherapeutics. To overcome disadvantages conventional approach, we used doxorubicin (DOX) as an ICD inducer, poly(lactic-co-glycolic acid) (PLGA)-based nanomedicine platform for controlled release DOX. The diameter 138.7 nm DOX-loaded PLGA nanoparticles...
Photodynamic therapy (PDT) is a promising strategy to promote antitumor immunity by inducing immunogenic cell death (ICD) in tumor cells. However, practical PDT uses an intense visible light owing the shallow penetration depth of light, resulting immunosuppression at tissues.Herein, we propose implantable micro-scale light-emitting diode device (micro-LED) guided that enables on-demand activation photosensitizers deep body potentiate with mild light.The micro-LED prepared stacking one four...
Nanomedicine has emerged as a promising strategy for cancer treatment. The most representative nanomedicine used in clinic is PEGylated liposomal doxorubicin DOXIL®, which first FDA-approved nanomedicine. However, several shortcomings, such low drug loading capacity, tumor targeting, difficulty mass production and potential toxicity of carrier materials, have hindered the successful clinical translation nanomedicines. In this study, we report preclinical development process carrier-free...
Cancer immunotherapy has revolutionized oncology by harnessing the patient’s immune system to target and eliminate cancer cells. However, checkpoint blockades (ICBs) face limitations such as low response rates, particularly in immunologically ‘cold’ tumors. Enhancing tumor immunogenicity through immunogenic cell death (ICD) inducers advanced drug delivery systems represents a promising solution. This review discusses development application of various nanocarriers, including polymeric...
Proteolysis-targeting chimeras (PROTACs) are a promising technique for the specific and durable degradation of cancer-related proteins via ubiquitin-proteasome system in cancer treatment. However, therapeutic efficacy PROTACs is restricted due to their hydrophobicity, poor cell permeability insufficient tumor-targeting ability. Herein, we develop self-assembled peptide-derived PROTAC nanoparticles (PT-NPs) precise programmed death-ligand 1 (PD-L1) targeted tumors. The PT-NPs with an average...
Prodrugs are bioreversible medications that should undergo an enzymatic or chemical transformation in the tumor microenvironment to release active drugs, which improve cancer selectivity reduce toxicities of anticancer drugs. However, such approaches have been challenged by poor therapeutic efficacy attributed a short half-life and low targeting. Herein, we propose cathepsin B-overexpressed cell activatable albumin-binding doxorubicin prodrug, Al-ProD, consists maleimide group, B-cleavable...
Glioma is a highly lethal tumor with poor prognosis, in which the presence of blood-brain barrier (BBB) and skull significantly limits treatment options. To address this, tumor-implantable optofluidic system (LED-SC), consisting microsized LED (microLED) microsyringe chip (SC), proposed to deliver both light prodrug nanoparticles (PNPs) directly brain glioma. The LED-SC combines microLED SC enable intratumoral administration PNPs for chemophotodynamic therapy. PNPs, self-assembled...
Immune checkpoint blockade (ICB) therapy targeting PD-L1 via monoclonal antibody (mAb) has shown extensive clinical benefits in the diverse types of advanced malignancies. However, most patients are completely refractory to ICB owing recycling mechanism. Herein, we propose photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes (immune liposomes; ICB-LPs) promote multivalent binding for inducing lysosomal degradation tumor cells. The ICB-LPs prepared by formulation DC8,9PC...
A prodrug is bioreversible medication that specifically converted to the active drugs by enzymes overexpressed in tumor microenvironment, which can considerably reduce chemotherapy-induced side effects. However, strategies usually have low antitumor efficacy compared free delayed drug release. This because they need time be activated enzymatic cleavage and also cannot fully recovered drugs. Therefore, highly potent anticancer should considered expect a sufficient efficacy. Herein, we propose...
Photothermal therapy (PTT) at mild temperatures ranging from 44 to 45 °C holds tremendous promise as a strategy for inducing potent immunogenic cell death (ICD) within tumor tissues, which can reverse the immunosuppressive microenvironment (ITM) into an immune-responsive milieu. However, accurately and precisely controlling temperature remains formidable challenge. Here, we report precision photothermal immunotherapy by using silica-coated gold nanorods (AuNR@SiO 2 ), investigating optimal...
Proteolysis‐targeting chimeras (PROTACs) are a promising technique for the specific and durable degradation of cancer‐related proteins via ubiquitin‐proteasome system in cancer treatment. However, therapeutic efficacy PROTACs is restricted due to their hydrophobicity, poor cell permeability insufficient tumor‐targeting ability. Herein, we develop self‐assembled peptide‐derived PROTAC nanoparticles (PT‐NPs) precise programmed death‐ligand 1 (PD‐L1) targeted tumors. The PT‐NPs with an average...
Abstract Background Nanomedicine has emerged as a promising strategy for cancer treatment. The most representative nanomedicine used in clinic is PEGylated liposomal doxorubicin DOXIL®, which first FDA-approved nanomedicine. However, several shortcomings, such low drug loading capacity and tumor targeting, difficulty mass production quality control (QC) potential toxicity of carrier materials, have hindered the additional clinical translation nanomedicines. In this study, we report...
Glass-to-glass electrostatic bonding has been developed for tubeless packaging of field emitter arrays (FEAs). Amorphous silicon film was deposited on 0080 glass by means RF sputtering method. In order to investigate the applicability this technique in-situ vacuum FED, hermetic sealing test FED panel whose exhausting hole sealed accomplished under 10/sup -7/ torr level.